Literature DB >> 21823044

Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome.

Nobuyuki Amemiya1, Takashi Takei, Chiari Kojima, Hirohiko Nokiba, Mitsuyo Itabashi, Kosaku Nitta.   

Abstract

Treatment with a single dose of rituximab alone induced remission in a patient with relapsed minimal change nephrotic syndrome (MCNS). A 27-year-old man was given corticosteroid (prednisolone; PSL) and cyclosporine (CyA) therapy combined with rituximab for his fifth relapse in 2008. Thereafter, complete remission was achieved and maintained despite eventual discontinuation of the PSL and CyA. In 2010, we treated his sixth relapse with a single dose of rituximab. Complete remission was obtained 32 days later. This is the first report of rituximab monotherapy in the treatment of MCNS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21823044     DOI: 10.1007/s10157-011-0510-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  11 in total

1.  T cells and minimal change disease.

Authors:  Robyn Cunard; Carolyn J Kelly
Journal:  J Am Soc Nephrol       Date:  2002-05       Impact factor: 10.121

2.  Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment.

Authors:  Mark D Pescovitz; Benita K Book; Richard A Sidner
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

3.  Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.

Authors:  Rodney D Gilbert; Eleanor Hulse; Susan Rigden
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

4.  T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome.

Authors:  Hicham Mansour; Lydie Cheval; Jean-Marc Elalouf; Jean-Christophe Aude; Maria-Alexandra Alyanakian; Béatrice Mougenot; Alain Doucet; Georges Deschênes
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

5.  Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse.

Authors:  H K Yap; W Cheung; B Murugasu; S K Sim; C C Seah; S C Jordan
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

6.  Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

Authors:  Graham C Smith
Journal:  Pediatr Nephrol       Date:  2007-02-20       Impact factor: 3.714

7.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

8.  Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.

Authors:  Y Sawara; M Itabashi; C Kojima; H Tabata; D Kamei; K Kawanishi; T Moriyama; H Sugiura; M Tsukada; T Takei; T Ogawa; T Yoshida; J Arai; K Uchida; K Tsuchiya; K Nitta
Journal:  Clin Nephrol       Date:  2009-07       Impact factor: 0.975

9.  Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.

Authors:  Vincent Guigonis; Aymeric Dallocchio; Véronique Baudouin; Maud Dehennault; Caroline Hachon-Le Camus; Mickael Afanetti; Jaap Groothoff; Brigitte Llanas; Patrick Niaudet; Hubert Nivet; Natacha Raynaud; Sophie Taque; Pierre Ronco; François Bouissou
Journal:  Pediatr Nephrol       Date:  2008-05-09       Impact factor: 3.714

Review 10.  Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide.

Authors:  Richard J Johnson; Abdias Hurtado; Justin Merszei; Bernardo Rodriguez-Iturbe; Lili Feng
Journal:  Am J Kidney Dis       Date:  2003-09       Impact factor: 8.860

View more
  3 in total

1.  Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.

Authors:  Andreas Kronbichler; Paul König; Martin Busch; Gunter Wolf; Gert Mayer; Michael Rudnicki
Journal:  Wien Klin Wochenschr       Date:  2013-04-27       Impact factor: 1.704

2.  Sustained complete remission of steroid- and cyclophosphamide-resistant minimal-change disease with a single course of rituximab therapy.

Authors:  Jyotsna Janardan; Khai Ooi; Solomon Menahem
Journal:  Clin Kidney J       Date:  2014-03-16

3.  Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy.

Authors:  Jin-Ying Fang; Yue Yang; Zheng Zhang; Shi-Min Jiang; Tian-Yu Yu; Wen-Ge Li
Journal:  Chronic Dis Transl Med       Date:  2020-02-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.